Breast Cancer Clinical Trial
Can HER2 Targeted PET/CT Imaging Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy?
Summary
Some breast cancer cells make a protein called Human Epidermal Growth factor receptor 2 (HER2). Patients with HER2 positive (HER2+) breast cancer receive medicine that attacks HER2, which helps these patients live longer. Some HER2 negative (HER2-) breast cancer patients also benefit from medicines that attack HER2, but we do not know why or which patients will benefit. This study uses a new imaging method, HER2-targeted PET/CT, to identify patients that may benefit from medicines that attack HER2. This is experimental.
Eligibility Criteria
Inclusion Criteria:
Women age > 18
Biopsy proven HER2 negative primary breast cancer and biopsy proven metastatic disease.
5 or more foci of demonstrable metastases on recent imaging modalities (CT, MR, FDG PET/CT)
ECOG performance score of 0-2
Exclusion Criteria:
Life expectancy < 3months
Pregnancy or lactation
Patients who cannot undergo PET/CT scanning because of weight limits
CNS only disease on recent imaging
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
New York New York, 10065, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.